Table 1 Characteristics of studies included in our meta-analysis (mo = months, NA = not available)
Study | Type of Cancer | Type of Drug Used | PARP Combo versus Mono | Male (%) | Average Age | Duration of follow-up | Total number of patients (n) | Somatic (n) | Germline | BRCA 1/2 breakdown | ORR rate for somatic | ORR rate for germline |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Dhawan | Multiple | Talazoparib | Combo | 83.3% | 59 (42–77) | NA | 24 | 1 | 7 | Somatic: 0/1 Germline: 3/4 | 0/1 | 3/7 |
Abida | Prostate | Rucaparib | Monotherapy | 100% | 71 (49–88) | 3.7 mo | 85 | 12 | 10 | NA | 5/10 | 5/10 |
Konstatintopaulos et al | Ovarian | Olaparib | Combo | 0% | 60 (55–67) | 12 mo | 34 | 3 | 10 | Somatic: 0/3 Germline: 7/5a | 1/3 | 3/10 |
Oza et al | Ovarian | Rucaparib | Monotherapy | 0% | 59 (33–84) | NA | 106 | 18 | 88 | Overall: 67/41 | 10/18 | 47/88 |
Mateo et al | Prostate | Olaparib | Monotherapy | 100% | 68 (41–73) | 14.4 mo | 50 | 4 | 3 | Overall: 0/7 | 4/4 | 3/3 |
Binder et al | Pancreatic | Rucaparib | Monotherapy | 15.8% | 61 (35–81) | NA | 24 | 1 | 16 | Somatic: 0/1 Germline: 3/13 | 1/1 | 6/16 |
Schroff et al | Pancreatic | Rucaparib | Monotherapy | 57.9% | 57 (41–75) | NA | 19 | 3 | 16 | Overall: 4/15 | 2/3 | 1/16 |
Piha Paul et al | Multiple | Talazoparib | Monotherapy | NA | NA | 15.8 mo | 35 | 1 | 7 | Na | 0/1 | 1/7 |